Crizotinib as a Personalized Alternative for Targeted Anaplastic Lymphoma Kinase Rearrangement in Previously Treated Patients With non-Small-Cell Lung Cancer

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s91988
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited


Related search